Skip to main content
letter
. 2021 Jul 20;23(5):e13688. doi: 10.1111/tid.13688

TABLE 1.

Recipient characteristics

Case number Age/Gender Type of transplant Primary disease for end‐stage kidney disease Positive donor SARS‐CoV‐2NP swab immediately prior to transplant SARS‐CoV‐2NP swab follow‐up after transplant Follow‐up period (days) Prior recipient vaccination Induction immunosuppression Graft outcome at last follow‐up Upper respiratory like symptoms at follow‐up
1 33/Female Kidney Lupus nephritis Yes Negative/9 days after transplant 84 No Thymoglobulin/basiliximab/methylprednisolon

Cr 0.8 mg/dl

BUN 17 mg/dl

None
2 21/Female Kidney Bilateral renal hypoplasia Yes Negative/9 days after transplant 84 1 Week prior to transplant (first dose‐Pfizer) Thymoglobulin/basiliximab/methylprednisolon

Cr 0.69 mg/dl

BUN 6 mg/dl

None
3 50/Female Kidney Atrophic kidneys No Negative/7 days after transplant 58 No Thymoglobulin/basiliximab/methylprednisolon

Cr 0.8 mg/dl

BUN 13 mg/dl

None
4 22/Male Liver Autoimmune hepatitis No Negative/13 days after transplant 35 Yes (two doses‐Pfizer) Methylprednisolone/antithymocyte/rituximab Normal liver function test None

Abbreviations: BUN, blood urea nitrogen; Cr, creatinine; NP, nasopharyngeal; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.